Nutra Pharma (NPHC) Stock Overview
A biopharmaceutical company, acquires, licenses, and commercializes pharmaceutical products and technologies, and drugs for the management of pain, neurological disorders, cancer, and autoimmune and infectious diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
NPHC Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Nutra Pharma Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0001 |
| 52 Week High | US$0.005 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 1 Month Change | -80.00% |
| 3 Month Change | 0% |
| 1 Year Change | 0% |
| 3 Year Change | -50.00% |
| 5 Year Change | -90.91% |
| Change since IPO | -99.83% |
Recent News & Updates
Recent updates
Shareholder Returns
| NPHC | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -90.0% | -0.7% | -0.2% |
| 1Y | 0% | 26.8% | 17.1% |
Return vs Industry: NPHC underperformed the US Biotechs industry which returned 26.8% over the past year.
Return vs Market: NPHC underperformed the US Market which returned 17.1% over the past year.
Price Volatility
| NPHC volatility | |
|---|---|
| NPHC Average Weekly Movement | 3,975.7% |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: NPHC's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine NPHC's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 6 | Michael Flax | www.nutrapharma.com |
Nutra Pharma Corp., a biopharmaceutical company, acquires, licenses, and commercializes pharmaceutical products and technologies, and drugs for the management of pain, neurological disorders, cancer, and autoimmune and infectious diseases in the United States. The company offers Nyloxin, an over-the-counter (OTC) pain reliever; Nyloxin Extra Strength, a non-narcotic and non-addictive treatment for severe pain; Pet Pain-Away, an OTC pain reliver for dogs and cats; Equine Pain-Away, an OTC topical pain reliever to relieve pain in horses; and Luxury Feet, an OTC pain reliever for foot pain from high heels and stilettos. It is also involved in developing RPI-78M to treat neurological and autoimmune diseases, including multiple sclerosis, adrenomyeloneuropathy, amyotrophic lateral sclerosis, rheumatoid arthritis, and myasthenia gravis; RPI-MN to treat viral diseases comprising human immunodeficiency virus/AIDS and herpes, and general anti-viral applications; RPI-78 for pain and arthritis; and RPI-70 for pain.
Nutra Pharma Corp. Fundamentals Summary
| NPHC fundamental statistics | |
|---|---|
| Market cap | US$709.97k |
| Earnings (TTM) | -US$1.32m |
| Revenue (TTM) | US$436.12k |
Is NPHC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NPHC income statement (TTM) | |
|---|---|
| Revenue | US$436.12k |
| Cost of Revenue | US$137.36k |
| Gross Profit | US$298.76k |
| Other Expenses | US$1.61m |
| Earnings | -US$1.32m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did NPHC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/30 09:22 |
| End of Day Share Price | 2025/12/29 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Nutra Pharma Corp. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.